Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salicylic acid + piroctone olamine is a topical combination therapy primarily used for the treatment of dandruff and seborrheic dermatitis of the scalp. Salicylic acid is a keratolytic agent that exfoliates and removes dead skin cells and flakes from the scalp, reducing scaling and facilitating penetration of other agents. Piroctone olamine is an antifungal compound that targets Malassezia species, the main pathogens involved in dandruff and seborrheic dermatitis, by disrupting fungal cell membranes and inhibiting fungal growth. The combination acts synergistically: salicylic acid clears scale and buildup, enabling piroctone olamine to more effectively reach and inhibit Malassezia, thereby controlling the underlying cause and symptoms of these scalp conditions. Clinically, this combination has demonstrated efficacy comparable to or slightly greater than that of zinc pyrithione-based shampoos, with noted improvements in flake reduction, symptom control, and scalp inflammation. Formulations containing this combination are most commonly found in medicated shampoos, scalp gels, or lotions for topical application[1][2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salicylic acid + piroctone olamine.